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Previous work has shown that versican, decorin and a
catabolic fragment of decorin, termed decorunt, are the
most abundant proteoglycans in human skin. Further
analysis of versican indicates that four major core protein
species are present in human skin at all ages examined
from fetal to adult. Two of these are identiﬁed as the V0
and V1 isoforms, with the latter predominating. The other
two species are catabolic fragments of V0 and V1, which
have the amino acid sequence DPEAAE as their carboxyl
terminus. Although the core proteins of human skin versi-
can show no major age-related differences, the glycosami-
noglycans (GAGs) of adult skin versican are smaller in
size and show differences in their sulfation pattern relative
to those in fetal skin versican. In contrast to human skin
versican, human skin decorin shows minimal age-related
differences in its sulfation pattern, although, like versican,
the GAGs of adult skin decorin are smaller than those of
fetal skin decorin. Analysis of the catabolic fragments of
decorin from adult skin reveals the presence of other frag-
ments in addition to decorunt, although the core proteins
of these additional decorin catabolic fragments have not
been identiﬁed. Thus, versican and decorin of human skin
show age-related differences, versican primarily in the size
and the sulfation pattern of its GAGs and decorin in the
size of its GAGs. The catabolic fragments of versican are
detected at all ages examined, but appear to be in lower
abundance in adult skin compared with fetal skin. In con-
trast, the catabolic fragments of decorin are present in
adult skin, but are virtually absent from fetal skin. Taken
together, these data suggest that there are age-related
differences in the catabolism of proteoglycans in human
skin. These age-related differences in proteoglycan pat-
terns and catabolism may play a role in the age-related
changes in the physical properties and injury response of
human skin.
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Introduction
The dermis is a tissue that contains an extensive extracellular
matrix, and its physical properties are determined primarily
by this matrix. Although collagen is the major extracellular
matrix molecule of the dermis (Pinnell and Murad 1983),
other molecular components are present and these com-
ponents also contribute to the overall mechanical properties of
skin. Among the non-collagenous components of the dermis
are proteoglycans (Bianco et al. 1990; Meyer and Stern 1994;
Zimmermann et al. 1994; Bernstein et al. 1995; du Cros et al.
1995; Bode-Lesniewska et al. 1996; Ågren et al. 1997;
Danielson et al. 1997; Carrino et al. 2000; Bayer-Garner et al.
2002). Previous analysis has shown that the most abundant
proteoglycans in extracts of postnatal human skin are decorin
and versican (Carrino et al. 2000). In addition, extracts of
postnatal human skin also contain a catabolic fragment of
decorin, termed decorunt, whereas virtually no decorunt, if
any, is detected in extracts of fetal human skin (Carrino et al.
2003). Another age-related difference observed with extracts
of human skin is the presence of a larger proportion of versi-
can in fetal compared with adult skin (Carrino et al. 2000).
Immunohistochemical analysis has revealed that versican
colocalizes with elastic ﬁbers in skin (Zimmermann et al.
1994; Bernstein et al. 1995), whereas decorin is known to
interact with collagen (Brown and Vogel 1989), to colocalize
with collagen in skin (Fleischmajer et al. 1991) and to be
crucial for robust tensile strength of skin through the estab-
lishment of a sound collagenous network (Danielson et al.
1997).
Because the mechanical properties of the dermis change as
a function of age (Daly and Odland 1979; Takema et al.
1994), and because the physical properties of the dermis are
determined principally by the extracellular matrix (Motokawa
and Tsuchi 2003; Ruggiero et al. 2005), age-related changes
in dermal extracellular matrix molecules are expected to be
involved in age-related changes in the mechanical properties
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of skin. Age-related differences have been reported for dermal
collagen (Bentley 1979; Lavker et al. 1987; Mays et al. 1988;
Yamauchi et al. 1988; Moragas et al. 1998). In order to
extend previous results regarding age-related differences in
skin proteoglycans (Carrino et al. 2000), versican and decorin
were isolated and analyzed from extracts of human skin
obtained from various ages. The analyses indicate that there
are differences between fetal and adult skin in the relative
amounts of versican and decorin, in the size and sulfation pat-
terns of the glycosaminoglycans (GAGs) of versican and in
the size of the GAGs of decorin. These age-related differences
in human skin versican and decorin have the potential to
result in functional differences in these molecules and, hence,
may be involved in the age-related changes in the biological
properties of human skin.
Results
Core proteins
The antibodies and antisera that were used to analyze the core
proteins of versican interact with deﬁned regions of the core
protein (Figure 1). Monoclonal antibody 12C5 recognizes an
epitope in the G1 region of versican (Asher et al. 1995). The
epitope for monoclonal antibody 2B1 (Isogai et al. 1996) is in
the G3 region (K Kimata, personal communication). The anti-
sera anti-GAG-α, anti-A and anti-D were raised against pep-
tides from the chondroitin sulfate-attachment region of
versican. Anti-GAG-α recognizes a peptide near the carboxyl-
terminal end of the GAG-α region (Dours-Zimmermann and
Zimmermann 1994), whereas anti-A and anti-D react with,
respectively, peptides near the amino-terminal end and at the
carboxyl-terminal end of the GAG-β region (Zimmermann
et al. 1994). Anti-DPEAAE and anti-NIVSFE are neoepitope
antisera (Sandy et al. 2001). As such, the peptides that they
recognize, DPEAAE and NIVSFE, respectively, must occur at
the carboxyl terminus in order for the antisera to react (Sandy
et al. 2001). These sequences were selected for antisera pro-
duction because of similarity to known ADAMTS (a disinte-
grin and metalloproteinase with thrombospondin motifs)-
mediated cleavage sites in human aggrecan and rat brevican
(Sandy et al. 2001). The NIVSFE sequence occurs near
the amino-terminal end of the GAG-α region, and it is there-
fore present in versican V0 and V2, but not V1
(Dours-Zimmermann and Zimmermann 1994). Cleavage at
this site by an ADAMTS generates a species of 66 kDa
from both V0 and V2, which reacts with the anti-NIVSFE
neoepitope antiserum (Westling et al. 2004). The DPEAAE
sequence occurs near the amino-terminal end of the GAG-β
region, and it is therefore present in versican V0 and V1,
but not V2 (Dours-Zimmermann and Zimmermann 1994).
This sequence is within the peptide recognized by anti-A
(Zimmermann et al. 1994). Cleavage at this site by an
ADAMTS generates a species of 66 kDa from V1 and a
much larger product from V0, 250 kDa in the results
reported herein. Both of these species are detected by the
anti-DPEAAE neoepitope antiserum (Sandy et al. 2001).
The results of the versican core protein analyses are sum-
marized in Figure 1 as indicated by the reactivities with the
various antibodies. The bands identiﬁed in the versican
immunoblots as bands 1–4 correspond, respectively, to the V0
isoform of versican, the V1 isoform, a catabolic fragment of
V0 and a catabolic fragment of V1. Irrespective of the donor
age, human skin samples show four major versican core
protein bands on immunoblots probed with monoclonal anti-
body 12C5 (Carrino et al. 2000; Figures 2–4, and data not
shown). Three of these, bands 1–3 (Figure 2), are recovered
in diethylaminoethyl (DEAE) pool 2 (i.e. the high-salt eluate
of the column), whereas one of these, band 4 (Figure 3), is
recovered in DEAE pool 1 (i.e. the low-salt eluate of the
column) and appears to lack chondroitin sulfate (Sorrell et al.
1999). In all the samples, fetal or adult, band 1 is much
fainter than bands 2 and 3 (Figures 2 and 4).
Like 12C5, anti-A recognizes all three of the versican core
protein isoforms recovered in DEAE pool 2 (bands 1–3,
Figure 2A). In contrast, anti-D recognizes only bands 1 and 2,
whereas anti-GAG-α recognizes only bands 1 and 3
(Figure 2A). The versican molecule recovered in DEAE pool
1 (i.e. band 4 of Figure 3) is not recognized by anti-D or
anti-GAG-α, but is recognized by anti-A (data not shown).
Another monoclonal antibody to the core protein of versican,
2B1, gives a pattern of reactivity like that of anti-D, that is,
bands 1 and 2 are recognized whereas bands 3 and 4 are not
recognized (Sorrell et al. 1999 and data not shown). Taken
together, these data indicate that bands 1 and 2 contain both
the amino- and the carboxyl-terminal regions of versican,
whereas bands 3 and 4 lack the carboxyl-terminal regions
(Figure 1).
The neoepitope antiserum anti-DPEAAE recognizes only
bands 3 and 4 (Figures 2 and 3), which suggests that these
bands are catabolic fragments of versican. Reactivity of bands
3 and 4 with anti-DPEAAE is consistent with these bands
lacking the carboxyl-terminal regions of versican. A second
Fig. 1. Antibody binding to the core protein of human versican. Shown
diagrammatically are the four major versican core protein species observed in
human skin and the locations at which various antibodies bind. N and C at
each end of the core protein diagram indicate the amino and carboxyl termini,
respectively. The brackets for those antibodies whose exact epitope is not
known (12C5 and 2B1) span the region in which the epitope is located. The
brackets for the polyclonal antisera (anti-GAG-α, anti-A and anti-D) span the
peptides used to raise the antisera. G1, G3, GAG-α and GAG-β refer to the
different regions of the versican core protein. Also shown are the reactivities
of the various antibody probes to the different human skin versican molecules
(+, reactivity observed; −, no detectable reactivity).
DA Carrino et al.
258
versican neoepitope antiserum, anti-NIVSFE, shows no reac-
tivity with samples of human skin proteoglycans, although a
positive control from human hippocampus shows the expected
66-kDa band (data not shown). Importantly, the only major
bands detected by 2B1 and anti-D are bands 1 and 2
(Figure 2 and data not shown); no other major bands are
detected. The pattern of reactivity obtained with anti-D and
2B1, which recognize different areas in the carboxyl region of
versican, suggests that the carboxyl portions of versican that
are generated by cleavage at the DPEAAE site are not
retained as such within the tissue, since such fragments
should contain chondroitin sulfate and, hence, should be
recovered in DEAE pool 2.
The results with samples of adult skin are qualitatively
similar to those obtained for fetal skin in that bands 1–3 are
detected on 12C5 immunoblots of DEAE pool 2 (Figure 4,
left panel). Like fetal samples, only bands 1 and 2 of adult
samples are recognized by 2B1 (Figure 4, middle panel), and
only band 3 of adult samples is recognized by anti-DPEAAE
(Figure 4, right panel). On 12C5 immunoblots, band 3 of
adult samples has a lower intensity relative to bands 1 and 2
than is observed for fetal samples (Figure 4, left panel).
The core proteins of decorin were also examined in proteo-
glycan samples from skin of various ages (Figure 5). For the
detection of human decorin core protein, immunoblots were
probed with monoclonal antibody 6B6, which recognizes
amino acids 57–65 of the core protein (Sawada et al. 2002).
After chondroitinase treatment of DEAE pool 2, 6B6 immu-
noblots revealed somewhat different patterns of decorin core
proteins for fetal and adult samples. The fetal samples that
were examined show two major decorin core protein bands
migrating at 45 kDa (Figure 5). In contrast, the adult
samples, which range in age from 19 to 82 years, show a
third decorin core protein band that migrates ahead of the
other two bands (Figure 5). For this study, it was possible to
obtain only one postnatal sample, which is 5 weeks of age.
This sample shows a pattern of decorin core proteins like
that of fetal skin rather than adult skin (Figure 5). The
6B6-positive band migrating at 14 kDa in the adult samples
is the core protein of the decorin catabolic fragment, decorunt
(Carrino et al. 2003).
Glycosaminoglycans
The chondroitin/dermatan sulfate of the major proteoglycans
extracted from human skin (versican, decorin and decorunt)
was analyzed after isolation of each of these proteoglycans.
The initial step in fractionating the different proteoglycans
for analysis of their GAGs involves separation of the large
proteoglycans (i.e. versican) from the small proteoglycans
(decorin, decorunt and biglycan) by Sepharose CL-2B chrom-
atography. This fractionation indicates that fetal skin contains
a larger proportion of versican than adult skin. As a pro-
portion of the total GAGs measured by Safranin O, fetal skin
contains 33.7 ± 7.9% of its GAGs as versican [n = 3, age
range 85–103 days estimated gestational age (EGA)], whereas
adult skin contains 3.3 ± 1.6% versican (n = 14, age range
20–56 years; data not shown). The larger proportion of versi-
can GAGs in fetal skin compared with adult skin correlates
with published results based on toluidine blue staining inten-
sity on sodium dodecyl sulfate polyacrylamide electrophoresis
(SDS–PAGE) and on composite agarose–polyacrylamide gels
(Carrino et al. 2000). This difference is also observed in the
staining intensity for versican core proteins on SDS–PAGE
and composite gel immunoblots (Carrino et al. 2000).
There are several differences in the disaccharide patterns of
the chondroitin/dermatan sulfate of versican from fetal skin com-
pared with adult skin (Table I). One major difference is in the
ratio of the two most abundant disaccharides, ΔDi6S [2-aceta-
mido-2-deoxy-3-O-(β-D-gluco-4-enepyranosyluronic acid)-6-O
Fig. 2. Versican core protein immunoblot analysis: DEAE pool 2. Proteoglycans isolated from two different samples of human fetal skin of 120 days EGAwere
eluted from an anion exchange column with 1 M sodium chloride, treated with chondroitinase ABC, subjected to sodium dodecyl sulfate polyacrylamide
electrophoresis (SDS–PAGE) on a 5% gel and electrotransferred to Immobilon-P. Separate blots were probed with the indicated antibody or antiserum. The blots in
(A) are from a blot transferred from one gel, whereas the blots in (B) are from a different gel. The three major bands detected with 12C5 are labeled 1, 2 and 3.
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-sulfo-D-galactose] and ΔDi4S [2-acetamido-2-deoxy-3-O-
(β-D-gluco-4-enepyranosyluronic acid)-4-O-sulfo-D-galactose].
Fetal skin versican contains 60% ΔDi6S and 20% ΔDi4S,
whereas adult skin versican contains somewhat more ΔDi4S
than ΔDi6S (Table I). Thus, the ratio of ΔDi6S to ΔDi4S is
3-fold higher for versican of fetal skin compared with the
average for versican across all adult skin samples. In addition,
the overall degree of sulfation is lower for fetal skin versican,
as indicated by the higher percentage of ΔDi0S [2-
acetamido-2-deoxy-3-O-(β-D-gluco-4-enepyranosyluronic acid)-
D-galactose] and by the calculated average number of sulfates
per disaccharide (Table I). The only oversulfated disaccharide
that is consistently detected in human skin versican is ΔDi2,6S
[2-acetamido-2-deoxy-3-O-(2-O-sulfo-β-D-gluco-4-enepyrano-
syluronic acid)-6-O-sulfo-D-galactose] (Table I). This disac-
charide is present at 2–4% and shows an increase in relative
amount in adult skin versican. There is also a general, though
not systematic, decrease in the size of the GAGs of human skin
versican in adult samples relative to fetal samples. It should be
noted that the determination of GAG chain length depends
heavily on the quantitative values obtained for the non-redu-
cing termini. These chain length determinations are, therefore,
greatly affected by even modest imprecision in the values
obtained for the non-reducing termini, which is potentially
problematic, because the non-reducing termini represent such a
small percentage of the total digestion products. Interestingly,
the non-reducing termini consistently show a higher level of
4-sulfation, even in fetal skin versican, where 6-sulfation
predominates in the internal disaccharides. Over the adult
age range examined (20–56 years), no signiﬁcant differences
were detected in the disaccharide composition of versican
(Table I).
Human skin decorin shows little age-related difference in
its GAGs (Table II). One major age-related difference is an
overall smaller size for the GAGs, a difference which is also
observed for versican. Unlike versican, the sulfation patterns
of the GAGs of human skin decorin show no major differ-
ences for fetal and adult samples. Adult skin decorin contains
consistently lower percentages of unsulfated and 6-sulfated
disaccharides compared with fetal skin decorin (Table II),
which mirrors differences in versican (Table I).
At each age examined, there are clear differences between
the GAGs of human skin versican and human skin decorin.
For example, the overall length of the GAGs of decorin is less
than that for versican (Tables I and II). Also, the sulfation pat-
terns of versican and decorin show several differences. While
versican contains no more than 51% ΔDi4S and no less than
36% ΔDi6S at any age examined, ΔDi4S comprises a substan-
tial percentage of the disaccharides in decorin, 83–88%, and
ΔDi6S is found in very low amounts, 4% or less (Tables I and
II). Human skin decorin differs further from versican in that it
contains ΔDi2,4S [2-acetamido-2-deoxy-3-O-(2-O-sulfo-β-D-
gluco-4-enepyranosyluronic acid)-4-O-sulfo-d-galactose]/ΔDi2,
4,6S [2-acetamido-2-deoxy-3-O-(2-O-sulfo-β-D-gluco-4-ene-
pyranosyluronic acid)-4,6-di-O-sulfo-D-galactose] as its major
oversulfated disaccharide, rather than ΔDi2,6S (Tables I and
II). Unlike versican, which shows consistently detectable
levels of only one oversulfated disaccharide, decorin displays
signiﬁcant amounts of a second oversulfated disaccharide,
ΔDi2,6S, which is present in the GAGs of human skin decorin
at levels of less than 2% (Tables I and II). At each age exam-
ined, decorin shows a higher level of sulfation than versican,
as indicated by the percentage of ΔDi0S and by the calculated
average number of sulfates per disaccharide, though the sulfa-
tion difference between versican and decorin is less pro-
nounced in adult skin than in fetal skin (Tables I and II). Like
versican, 4-sulfation predominates at the non-reducing termini
of human skin decorin (Tables I and II). Not surprisingly, the
disaccharide analysis of decorunt gives results that are similar
to those obtained for decorin (Tables II and III). This similarity
is expected, since there is evidence that decorunt is a catabolic
fragment of decorin, which presumably arises by proteolytic
cleavage of decorin (Carrino et al. 2003).
Decorin catabolic fragments
Decorunt consists of the amino-terminal 40% of decorin with
the amino acid sequence VRKVTF140 as its carboxyl terminus
Fig. 3. Versican core protein immunoblot analysis: DEAE pool 1. Material
isolated from eight different samples of human skin of the indicated ages and
recovered in DEAE pool 1 was subjected to immunoblot analysis for versican
core proteins. Each of the two different samples of fetal skin is 120 days
EGA. Samples were subjected to SDS–PAGE on 5–17.5% gradient gels, and
the gels were electrotransferred to Immobilon-P. Separate blots were probed
with 12C5 (upper panel) or anti-DPEAAE (lower panel). The major band
detected with 12C5 is labeled band 4.
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(Carrino et al. 2003). It was previously found that decorunt
can be separated from decorin by chromatography on octyl-
Sepharose and that decorunt can be identiﬁed on immunoblots
by its speciﬁc reactivity with a neoepitope antiserum, anti-
VRKVTF, which was generated to recognize the carboxyl ter-
minus of decorunt and which does not recognize decorin
(Carrino et al. 2003).
Further analysis of decorunt revealed additional decorin
catabolic fragments, which are termed non-decorunt catabolic
fragments of decorin. The non-decorunt fragments were ﬁrst
observed when a new lot of octyl-Sepharose was purchased
to replace the depleted lot that was used for the initial
fractionations of decorunt from decorin. Both lots were pro-
cured from the same supplier under the same catalog number.
With the original lot of octyl-Sepharose, decorunt eluted in
the column unbound, whereas decorin bound to the column
and was eluted during the guanidinium chloride gradient
(Carrino et al. 2003). With the new lot, both decorin and dec-
orunt bound to the column and eluted at a similar concen-
tration of guanidinium chloride, whereas a distinct population
of decorin catabolic fragments eluted in the column unbound.
This is evident by immunoblot comparison of samples chro-
matographed on the old and new lots of octyl-Sepharose. On
immunoblots probed with anti-VRKVTF, decorunt is detected
Fig. 4. Versican core protein analysis: Adult skin samples. Versican core protein analysis was done on proteoglycans recovered in DEAE pool 2 for three
different samples of adult human skin of the indicated ages and three different samples of fetal human skin of the indicated EGA. Samples were treated with
chondroitinase ABC, subjected to SDS–PAGE on a 5% gel and electrotransferred to Immobilon-P. Separate blots were probed with the indicated antibody or
antiserum. The three major bands detected with 12C5 are labeled 1, 2 and 3 and correspond to the same bands indicated in Figure 2.
Fig. 5. Decorin core protein analysis. Decorin core protein analysis was done on proteoglycans recovered in DEAE pool 2 for 16 different samples of skin of the
indicated ages. The two different 103 days EGA fetal samples are from the same individual, one trunk skin (left panel) and the other scalp skin (right panel).
Samples were treated with chondroitinase ABC, subjected to SDS–PAGE on a 5–17.5% gradient gel and electrotransferred to Immunobilon-P. The blots were
probed with 6B6.
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in the unbound pool with the old lot and in pool 2 with the
new lot (Figure 6, lower panels). On immunoblots probed
with 6B6, which recognizes decorin and decorin catabolic
fragments, a reactive band migrating between 45 and 31 kDa
is observed in the column unbound for both lots, whereas a
faint band migrating at a similar position is detected in pool 2
for the sample chromatographed on the new lot (Figure 6,
upper panels). This latter band presumably represents dec-
orunt. For both lots, decorin, the 6B6-positive band migrating
between 80 and 100 kDa, elutes in pool 2 (Figure 6, upper
panels). Similar results are obtained with proteoglycans from
two other adult skin samples (data not shown). When aliquots
from two samples were separately chromatographed on the
two lots of octyl-Sepharose, the fractionation conformed to
the speciﬁc lot (data not shown).
On the basis of the results with the new lot of octyl-
Sepharose, the 6B6-reactive material that did not bind to the
old lot of resin is now interpreted to contain both decorunt
and the non-decorunt catabolic fragments of decorin. The
Table I. Human skin versican disaccharide analysis
Disaccharide Fetal Adult
85 days 103 daysa 103 daysa 20 years 24 years 37 years 52 years 56 years
ΔDi0S (%) 14.1 12.2 18.3 5.4 7.2 4.0 10.4 3.2
ΔDi6S (%) 61.7 62.7 54.2 43.3 38.2 38.1 35.9 44.1
ΔDi4S (%) 21.3 21.8 23.9 45.9 47.3 51.1 48.8 45.1
ΔDi2S ND ND ND ND ND ND ND ND
ΔDi4,6S (%) ND ND ND 0.6 0.6 ND ND ND
ΔDi2,6S (%) 2.1 2.4 2.6 3.5 4.3 4.3 3.6 3.8
ΔDi2,4S/ΔDi2,4,6S (%) ND ND ND ND 0.8 ND ND ND
6S-GalNAc (%) 0.3 0.1 0.3 0.4 0.5 1.2 0.3 1.6
4S-GalNAc (%) 0.5 0.9 0.8 0.9 1.2 1.3 1.1 2.1
Chain lengthb 131 99 87 77 58 39 74 26
Sulfationc 0.87 0.89 0.83 0.97 0.95 0.98 0.92 0.97
ND, not detected; 6S-GalNAc, N-acetylgalactosamine-6-sulfate; 4S-GalNAc, N-acetylgalactosamine-4-sulfate; ΔDi2S, 2-acetamido-2-deoxy-3-O-(2-O-sulfo-β-D-
gluco-4-enepyranosyluronic acid)-D-galactose.
aThese proteoglycan samples are from the same individual (column 3, trunk skin; column 4, scalp skin).
bNumber averaged disaccharides per GAG chain.
cAverage sulfates per disaccharide.
Table II. Human skin decorin disaccharide analysis
Disaccharide Fetal Adult
85 days 103 daysa 103 daysa 20 years 24 years 37 years 42 years 49 years 52 years 56 years
ΔDi0S (%) 2.8 4.3 3.4 1.7 1.9 1.4 1.6 1.9 0.8 0.9
ΔDi6S (%) 6.3 7.3 6.4 3.6 2.3 2.8 3.4 0.8 1.5 2.5
ΔDi4S (%) 85.1 83.0 84.5 86.1 86.1 86.8 83.5 88.4 87.7 88.5
ΔDi2S ND ND ND ND ND ND ND ND ND ND
ΔDi4,6S ND ND ND ND ND ND ND ND ND ND
ΔDi2,6S (%) 0.7 1.3 0.9 1.0 0.9 0.8 1.1 1.2 1.6 0.3
ΔDi2,4S/ΔDi2,4,6S (%) 3.2 2.6 2.7 4.9 5.5 5.0 6.4 5.3 5.0 4.5
6S-GalNAc (%) 0.5 0.1 0.2 0.4 0.1 0.01 0.2 0.2 0.1 0.1
4S-GalNAc (%) 1.4 1.5 2.0 2.4 3.1 3.1 3.8 2.3 3.2 3.3
Chain lengthb 52 64 45 35 30 30 24 39 29 29
Sulfationc 1.0 1.0 1.0 1.1 1.1 1.1 1.1 1.1 1.1 1.1
ND, not detected; 6S-GalNAc, N-acetylgalactosamine-6-sulfate; 4S-GalNAc, N-acetylgalactosamine-4-sulfate; ΔDi2S, 2-acetamido-2-deoxy-3-O-(2-O-sulfo-β-D-
gluco-4-enepyranosyluronic acid)-D-galactose.
aThese proteoglycan samples are from the same individual (column 3, trunk skin; column 4, scalp skin).
bNumber averaged disaccharides per GAG chain.
cAverage sulfates per disaccharide.
Table III. Human skin decorunt disaccharide analysis
Disaccharide Adult
20
years
24
years
37
years
42
years
49
years
52
years
56
years
ΔDi0S (%) 1.6 1.8 0.8 1.7 1.5 1.4 1.2
ΔDi6S (%) 4.1 2.7 1.9 3.6 2.2 4.7 4.0
ΔDi4S (%) 86.0 85.5 85.5 83.2 86.9 82.7 85.9
ΔDi2S ND ND ND ND ND ND ND
ΔDi4,6S (%) 0.3 ND ND ND ND ND ND
ΔDi2,6S (%) 1.0 0.9 ND 1.2 2.0 ND 0.4
ΔDi2,4S/ΔDi2,4,6S (%) 4.4 6.1 8.2 6.4 5.1 7.2 5.0
6S-GalNAc (%) 0.4 0.2 0.9 0.3 0.2 1.3 0.5
4S-GalNAc (%) 2.1 2.7 2.6 3.6 2.2 2.7 3.0
Chain lengtha 40 33 27 25 42 24 28
Sulfationb 1.1 1.1 1.1 1.1 1.1 1.1 1.1
ND, not detected; 6S-GalNAc, N-acetylgalactosamine-6-sulfate; 4S-GalNAc,
N-acetylgalactosamine-4-sulfate; ΔDi2S, 2-acetamido-2-deoxy-3-O-(2-O-
sulfo-β-D-gluco-4-enepyranosyluronic acid)-D-galactose.
aNumber averaged disaccharides per GAG chain.
bAverage sulfates per disaccharide.
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samples that were used for GAG analysis of decorunt
(Table III) were prepared with the old lot. Thus, both decorunt
and the non-decorunt fragments were included in this analy-
sis. A third lot of octyl-Sepharose, which was subsequently
purchased, has elution characteristics like those of the new lot
(data not shown). The basis for the difference in the elution
properties of the old and the new lots of octyl-Sepharose is
not clear but may result from differences in the number and/or
distribution of the octyl groups on the resin, which may affect
the binding properties of the resin.
Owing to their lack of reactivity with anti-VRKVTF, the
6B6-reactive bands recovered in the column unbound with the
new lot differ from decorunt in their carboxyl termini. Their
retention by anion exchange chromatography indicates that
these molecules contain the GAG attached to serine-4 of
mature decorin and, hence, have amino termini which are not
truncated beyond this amino acid. Because of this and based
on the known location of the 6B6 epitope within the core
protein of decorin (Sawada et al. 2002), any protein com-
ponents of the non-decorunt catabolic fragments of decorin
should be at least 4.2 kDa. Chondroitinase ABC-treated ali-
quots of these fragments were analyzed on Coomassie blue-
stained tris-tricine gels and on 6B6 immunoblots of tris-
tricine gels. However, no protein bands could be identiﬁed as
the core proteins of the non-decorunt fragments in spite of
repeated attempts with several different skin samples (data not
shown). It is possible that the non-decorunt fragments, in con-
trast to decorunt, do not have a deﬁned carboxyl terminus, so
that the protein components of these fragments are too hetero-
geneous in size to give rise to distinct bands on gel electro-
phoresis. Taken together, these results indicate that adult
human skin contains additional catabolic fragments of decorin
besides decorunt and also indicate that there can be differ-
ences in the elution characteristics of different lots of
octyl-Sepharose.
Discussion
Previous work identiﬁed three major proteoglycans in human
skin: versican, decorin and a catabolic fragment of decorin,
termed decorunt (Carrino et al. 2000, 2003). Biglycan was also
detected, but is present at lower amounts (Carrino et al. 2000).
In these studies, detailed structural characterization of versican
and decorin was not performed. With respect to versican, the
data in this report indicate that four core protein species are
most prominent: the V0 and V1 splice variants and the cata-
bolic fragments of these molecules with DPEAAE as the car-
boxyl termini. This determination is based on the pattern of
reactivity with antibodies to deﬁned locations within the core
protein of versican (Figure 1). As indicated by the relative
intensities of the bands detected with 12C5, the V1 isoform is
more abundant than the V0 isoform in human skin. This corre-
lates with results obtained at the transcriptional level by reverse
transcriptase–polymerase chain reaction (Cattaruzza et al.
2002) and at the translational level with cultured human dermal
ﬁbroblasts (Zimmermann et al. 1994). The results presented in
this report indicate that these relative amounts of V0 and V1
also occur at the translational level in vivo.
In the present study, no evidence was found for the V2 and
V3 isoforms in human skin. The V2 isoform has been detected
only in the central nervous system (Schmaltfeldt et al. 1998;
Zimmermann and Dours-Zimmermann 2008; Dours-
Zimmermann et al. 2009), and its absence from skin is consist-
ent with this observation. The V3 isoform lacks both of the
GAG-attachment regions (GAG-α and GAG-β) and, hence,
should not contain GAGs (Zako et al. 1995). As such, the
expectation is that V3 does not bind to DEAE-Sephacel and
would be excluded from the proteoglycan analysis described in
this report. However, since V3 contains the G1 region, this
isoform should bind to DEAE-Sephacel for the same reasons
that the catabolic fragment of V1 does, as described later in the
Discussion. Thus, if V3 is present in human skin, it should be
detected on 12C5 immunoblots of DEAE pool 1 as a band
migrating at 75 kDa, and no such band is observed
(Figure 3). This suggests that V3 is not present in skin at the
protein level, although V3 has been reported in skin at the tran-
scriptional level (Cattaruzza et al. 2002).
On the basis of their patterns of antibody reactivity
(Figure 1), bands 3 and 4 of Figures 2–4 are identiﬁed as
Fig. 6. Octyl-Sepharose chromatography of proteoglycans on different lots
of octyl-Sepharose: column pools. Two different samples of proteoglycans
recovered in DEAE pool 2 were chromatographed on Sepharose CL-2B to
separate versican from the small proteoglycans, and the small proteoglycans
were further fractionated on octyl-Sepharose. Each sample was fractionated
on a different lot of octyl-Sepharose, designated the old lot or the new lot.
Aliquots of each octyl-Sepharose pool were subjected to SDS–PAGE on a
5–17.5% gradient gel and electrotransferred to Immunobilon-P. Separate blots
were probed with either 6B6 (upper panels) or anti-VRKVTF (lower panels).
For comparison, a lane of unfractionated material was also included. The
migration positions of decorin and decorin catabolic fragments are indicated.
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catabolic fragments of V0 and V1, G1-DPEAAE1428 and
G1-DPEAAE441, respectively, according to the nomenclature
of Sandy et al. (2001). The latter should lack chondroitin
sulfate, as is observed for this molecule (Sorrell et al. 1999).
A molecule similar in size to band 4 and recognized by 12C5
has been observed in extracts of central nervous system tissue
(Asher et al. 1991, 1995). This molecule was found to have a
low isoelectric point (Asher et al. 1991), which likely explains
the binding of band 4 to the anion exchange columns. Band 4
is not recognized by the neoepitope antiserum anti-NIVSFE.
Cleavage of the V0 isoform at this site would be expected to
give rise to a fragment, G1-NIVSFE405, which would have a
size similar to that of the V1 fragment, G1-DPEAAE441, and
also be devoid of chondroitin sulfate. The lack of reactivity
with anti-NIVSFE suggests that, in human skin, versican frag-
ments terminating in DPEAAE are the major fragments that
accumulate, and cleavage at the NIVSFE site may not occur.
The G1-DPEAAE1428 and the G1-DPEAAE441 fragments are
also present in human aortic intima (Sandy et al. 2001).
The relative intensities of bands detected with 12C5 in fetal
and adult skin suggest that there is a lower level of versican
catabolism in adult skin compared with fetal skin, although
other interpretations are possible. The metalloproteinases
ADAMTS1 and ADAMTS4 have been shown to cleave versi-
can at DPEAAE (Sandy et al. 2001), and the former has been
detected in skin (Krampert et al. 2005). It has previously been
reported that versican, through its G3 domain, has the
capacity to interact with ﬁbrillin-1 and that this interaction is
not abrogated by 4 M guanidinium chloride (Isogai et al.
2002). Thus, the possibility exists that the carboxyl regions
removed from versican by cleavage at DPEAAE are not
detected among the extracted molecules because these frag-
ments are not efﬁciently extracted from the tissue, although in
the present study, extraction was performed with not only 4 M
guanidinium chloride, but with this chaotropic agent plus
detergent.
Although versican shows no qualitative age-related differ-
ences in its pattern of core proteins, a small age-related differ-
ence is observed in the polydispersity of decorin core
proteins. The fetal samples show a pattern of decorin core
proteins similar to previous observations (Glössl et al. 1984;
Scott and Dodd 1990; Schönherr et al. 1993; Ramamurthy
et al. 1996), whereas adult samples show an additional band
with higher mobility. It is not known if the differences in
decorin core protein polydispersity result from differences in
the number of asparagine-linked oligosaccharides or retention
of the propeptide in some decorin molecules (Sawhney et al.
1991) or if the smallest of the three major decorin core
protein bands in the adult samples results from catabolism.
Because the core protein of decorin is involved in a number
of molecular interactions (Brown and Vogel 1989; Schönherr
et al. 1998; Santra et al. 2002), the possibility exists that there
are age-related differences in fetal and adult skin with regard
to the core protein-mediated interactive properties of decorin,
such as its binding to collagen, which may affect the tensile
properties of skin (Danielson et al. 1997).
Versican, but not decorin, shows age-related differences in
the disaccharide pattern of its GAGs. For the ages examined,
differences are found only between fetal skin versican and
adult skin versican. The differences in disaccharide compo-
sition observed for versican from fetal and adult human skin
represent, to our knowledge, the ﬁrst such differences reported
for this proteoglycan, although age-related disaccharide
pattern differences have been reported for aggrecan from a
number of species (De Luca et al. 1977; Roughley and White
1980; Thonar and Sweet 1981, Madsen et al. 1983;
Dziewiatkowski et al. 1989). Age-related differences have
also been reported for the disaccharide composition of
heparan sulfate of human abdominal aorta (Feyzi et al. 1998).
The GAGs of versican have been shown to be involved in
interaction of this proteoglycan with other molecules, such as
selectin, CD44 and chemokines (Kawashima et al. 2000; Zou
et al. 2000). For at least some of these interactions, evidence
indicates that the oversulfated disaccharide ΔDi4,6S [2-aceta-
mido-2-deoxy-3-O-(β-D-gluco-4-enepyranosyluronic acid)-4,6-
di-O-sulfo-D-galactose] is critical (Kawashima et al. 2002;
Zou et al. 2003). Because virtually none of this disaccharide
is detected in human skin versican, it is expected that human
skin versican does not participate in interactions that require
ΔDi4,6S. The different disaccharide compositions of fetal and
adult versican may result in differences in the interactive prop-
erties of this proteoglycan, which may affect the biological
properties of human skin.
Versican has also been demonstrated to inﬂuence cell
migration (Evanko et al. 2001; Dutt et al. 2006). A chondroi-
tin/dermatan sulfate proteoglycan, later determined to be the
murine homolog of phosphacan, has been shown to promote
neurite outgrowth due to its GAG structure (Faissner et al.
1994). The important component of the GAGs for this
activity was determined to be ΔDi2,6S (Clement et al. 1998),
which is present in human skin versican at all ages examined.
Thus, versican in skin may be involved in promoting cell
migration. In addition, elevated levels of versican have been
found in highly proliferative tissues, such as tumors (Isogai
et al. 1996; Paulus et al. 1996; Nara et al. 1997; Brown et al.
1999; Sakko et al. 2001; Ricciardelli et al. 2002; Touab et al.
2002). Versican from tumors has been shown to contain a
higher percentage of ΔDi6S and ΔDi0S relative to versican
from normal tissues (Tsara et al. 2002; Theocharis et al.
2003). These differences in the amount and disaccharide com-
position of versican from tumors and non-tumor tissue corre-
late with the differences between fetal skin versican and adult
skin versican. Hence, the relative amount and the sulfation
pattern of fetal skin versican may contribute to higher cell
proliferation in fetal skin. Little information is available in
relation to possible effects of versican on dermal repair.
Excisional wound studies in mice have shown that
ADAMTS5 knockouts do not generate a normal collagenous
matrix in the subepithelial region during repair (Velasco et al.
2010). This abnormal repair is preceded by the accumulation
and subsequent removal of versican V1. This might be
explained if the versican accumulation represents a dysregu-
lated response of reparative cells to proinﬂammatory factors.
With regard to the disaccharide composition of human skin
versican, it is important to note that immunohistochemistry
with antibodies that recognize discrete structural motifs in
chondroitin sulfate indicate that there are spatially speciﬁc
localizations of distinct chondroitin sulfate structures (Sorrell
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et al. 1999). Restricted distributions of carbohydrate epitopes,
which were attributed to versican, have also been reported for
other tissues (Cattaruzza et al. 2002). Thus, although the bio-
chemical analysis of the GAGs of extracted human skin versi-
can measures only the disaccharide pattern of the total
population of this tissue’s versican molecules, within the
tissue, there is a regionalization of versican molecules having
speciﬁc GAG structural compositions. These spatial variations
in the structure of the GAGs of versican may be involved in
regional differences in the interactive or other functional prop-
erties of dermal versican, which are expected to be different
for fetal and adult skin because of the age-related differences
in versican’s disaccharide composition. Although human skin
versican shows clear age-related differences in its disaccharide
composition, no major age-related differences are detected for
human skin decorin. The decrease in decorin GAG length cor-
relates with a previously observed age-related decrease in
overall size of human skin decorin (Carrino et al. 2000).
Dermatan sulfate from decorin and biglycan of mouse tendon
displays an age-related decrease in size and an increase in the
oversulfated disaccharide ΔDi2,4S (Derwin et al. 2001). The
same may be true for human skin decorin if the small but
consistent increase in ΔDi2,4S/ΔDi2,4,6S observed for adult
skin decorin is due to ΔDi2,4S.
The results presented herein add further details to the analy-
sis of the age-related changes in the proteoglycans of human
skin. The age-related differences in proteoglycan structure and
catabolism may play a role in age-related differences in the
biological properties and the injury response of skin.
Materials and methods
Materials
The sources of reagents and other supplies have been reported
previously (Carrino et al. 2000, 2003). Samples of human
skin of various fetal and adult ages were obtained in accord-
ance with the policies established by the Institutional Review
Board of Case Western Reserve University (Carrino et al.
2000, 2003). Samples of fetal human skin were procured
through the Central Laboratory for Human Embryology at the
University of Washington, Seattle, WA, and samples of adult
human skin were obtained through the Tissue Procurement
Core Facility, Cancer Center, Case Western Reserve
University, Cleveland, OH.
Proteoglycan extraction, isolation and fractionation
Proteoglycans were extracted from minced human skin and
isolated by anion exchange chromatography on DEAE-
Sephacel as described previously (Carrino et al. 2000). The
anion exchange columns were eluted in a stepwise manner
with 0.25 M and then 1.0 M sodium chloride (Carrino et al.
2000). The lower salt eluate, designated DEAE pool 1, con-
tains hyaluronan and some loosely bound glycoproteins,
whereas the higher salt eluate, designated DEAE pool 2, con-
tains the sulfated proteoglycans (Carrino et al. 2000).
The various proteoglycans in DEAE pool 2 (versican,
decorin, decorunt and biglycan) were separated by Sepharose
CL-2B and octyl-Sepharose chromatography as reported pre-
viously (Carrino et al. 2003). All of the different lots of
octyl-Sepharose were obtained from Sigma-Aldrich, catalog
number O6001. Fractions for both columns were assayed by
dot blots with appropriate antibodies. For the Sepharose CL-
2B column, fractions that contained versican and fractions that
contained the small proteoglycans (decorin, decorunt and
biglycan) were pooled separately. The latter pool was further
fractionated by octyl-Sepharose chromatography to generate
separate pools that contain decorin, decorunt or biglycan. The
amount of GAG in each of the column pools was determined
by a Safranin O assay (Carrino et al. 1991). The fractionated
samples of versican, decorin and decorunt were used for
GAG analysis; GAG analysis was not done for biglycan due
to insufﬁcient material.
SDS–PAGE and immunoblotting
Electrophoresis on polyacrylamide gels, electrotransfer to
Immobilon-P and immunoblotting were performed as described
(Carrino et al. 2000). Samples were examined either as intact
proteoglycans or as core proteins after treatment with chondroi-
tinase ABC (Carrino et al. 2000). All the proteoglycan samples
were subjected to core protein immunoblot analysis, but results
are shown only for some of the samples. Those samples for
which core protein results are not presented gave results like
those for samples in the same age group (fetal or adult).
To analyze the catabolic fragments of decorin and their
core proteins, the different pools from the octyl-Sepharose
column were electrophoresed on tris-tricine polyacrylamide
gels in order to increase the resolution of small proteins. For
immunoblots of these gels, a procedure was used that
enhances the binding of small proteins to the blotting mem-
brane. This procedure was used because decorin catabolic
fragments and their core proteins are not retained well on
Immobilon-P immunoblotting membrane under the conditions
routinely used for immunoblots (Carrino et al. 2000, 2003).
The tris-tricine gels were electrotransferred onto Immobilon-
PSQ and the blots were air dried for 1 h at room temperature.
Then the blots were moistened brieﬂy in methanol, rinsed
with water and blocked for 30 min in 3% enzyme-linked
immunosorbent assay ELISA-grade bovine serum albumin
(BSA) in TBS-Tween [tris-buffered saline containing 0.05%
Tween-20 (polyoxyethylenesorbitan monolaurate)]. The blots
were then incubated for 1 h in primary antibody diluted into
3% BSA in TBS-Tween, rinsed with TBS-Tween, incubated
for 1 h in alkaline phosphatase–conjugated secondary anti-
body diluted into TBS-Tween, rinsed with TBS-Tween and
ﬁnally incubated in alkaline phosphatase substrate.
GAG analysis
The disaccharide compositions of GAGs were determined as
reported previously (Calabro et al. 2000a, 2000b). Samples of
individual proteoglycans were treated with a combination of
chondroitinase ABC and hyaluronidase SD (Streptococcus
dysgalactiae). The digestion products were ﬂuorescently
labeled and then fractionated and quantiﬁed by a ﬂuorophore-
assisted carbohydrate electrophoresis procedure (Calabro,
Benavides, et al. 2000; Calabro, Hascall, et al. 2000).
Because this procedure does not resolve ΔDi2,4S and
ΔDi2,4,6S, the band containing these disaccharides is desig-
nated ΔDi2,4S/ΔDi2,4,6S to indicate that this band may
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contain either of these or a mixture of these. In addition to
disaccharide compositions, this procedure also allows esti-
mation of the number averaged size of the GAGs by quantiﬁ-
cation of the internal disaccharides and the non-reducing
termini. The GAG analyses were performed for one aliquot of
each sample that was analyzed. To assess reproducibility,
some of the samples (a total of six) were analyzed in dupli-
cate, and these duplicate analyses showed no signiﬁcant
differences (data not shown). GAG analysis was performed
only for those samples for which results are presented.
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Abbreviations
ΔDi6S, 2-acetamido-2-deoxy-3-O-(β-D-gluco-4-enepyranosyluro-
nic acid)-6-O-sulfo-D-galactose; ΔDi4S, 2-acetamido-2-deoxy-3-
O-(β-D-gluco-4-enepyranosyluronic acid)-4-O-sulfo-D-galactose;
ΔDi0S, 2-acetamido-2-deoxy-3-O-(β-D-gluco-4-enepyranosyluro-
nic acid)-D-galactose; ΔDi2,6S, 2-acetamido-2-deoxy-3-O-(2-O-
sulfo-β-D-gluco-4-enepyranosyluronic acid)-6-O-sulfo-D-galac-
tose; ΔDi2,4S, 2-acetamido-2-deoxy-3-O-(2-O-sulfo-β-D-gluco-
4-enepyranosyluronic acid)-4-O-sulfo-d-galactose; ΔDi4,6S, 2-
acetamido-2-deoxy-3-O-(β-D-gluco-4-enepyranosyluronic acid)-
4,6-di-O-sulfo-D-galactose; ΔDi2,4,6S, 2-acetamido-2-deoxy-3-
O-(2-O-sulfo-β-D-gluco-4-enepyranosyluronic acid)-4,6-di-O-
sulfo-D-galactose; ADAMTS, a disintegrin and metalloprotei-
nase with thrombospondin motifs; BSA, bovine
serum albumin; DEAE, diethylaminoethyl; EGA, estimated
gestational age; GAG, glycosaminoglycan; TBS-Tween, tris-
buffered saline containing 0.05% Tween-20 (polyoxyethy-
lene-sorbitan monolaurate).
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